Ebb Therapeutics

About Ebb Therapeutics

Ebb Therapeutics, formerly known as Cerêve Inc., was established in 2008 by Eric Nofzinger, M.D., a distinguished psychiatrist and sleep medicine expert. The company’s genesis is rooted in Dr. Nofzinger's extensive, multi-decade research at the University of Pittsburgh School of Medicine, where his pioneering brain imaging studies identified a key cause of sleeplessness: hyperactivity in the brain's frontal cortex. This scientific journey led to the development of a novel, drug-free therapeutic approach to address insomnia. The company's business model focused on developing and selling these therapeutic devices directly to consumers and through medical channels.

The core offering from Ebb Therapeutics is a wearable device that uses proprietary cooling technology to manage sleeplessness. The product line has included the prescription-based Ebb Insomnia Therapy and the direct-to-consumer Ebb with Precision Cool Technology, later marketed as the Ebb CoolDrift Luxe and Versa models. These devices consist of a soft, fluid-filled headband connected to a compact bedside controller. This system precisely cools the user's forehead, which reduces the metabolic activity in the frontal cortex, thereby calming a 'racing mind' and allowing the body's natural sleep drive to take over. The technology received FDA clearance as a Class II medical device, validating its ability to reduce the time it takes to enter the initial stages of sleep. Unlike pharmaceutical options, this method is free of side effects like dependency or memory loss.

Financially, Ebb Therapeutics attracted significant investment to fuel its research and commercialization efforts. The company raised a total of approximately $45-51 million through several funding rounds, including an initial grant from the National Institutes of Health. Key investors included prominent firms like KKR, Arboretum Ventures, and Versant Ventures, with a substantial $38 million Series B round closing in January 2017. This funding was instrumental in scaling manufacturing and launching the product nationally. In a significant strategic move, Ebb Therapeutics merged with Kryo Inc., the parent company of ChiliSleep, in December 2020. This merger, supported by a $37 million investment led by KKR, aimed to create a market leader in temperature-regulating sleep solutions by combining Ebb's wearable technology with ChiliSleep's hydro-powered mattress systems.